X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under terms of the Agreement, Pfizer will deploy a team across Canada to support education about Vascepa with primary care physician ("PCP") groups.
Lead Product(s): Icosapent Ethyl
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vascepa
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 16, 2021
Details:
Vascepa COVID-19 CardioLink-9 Randomized Trial suggests improvement in patient-reported COVID-19 symptoms while demonstrating a 25% reduction in high-sensitivity C-reactive protein with encouraging short-term safety and tolerability data using Vascepa loading dose.
Lead Product(s): Icosapent Ethyl
Therapeutic Area: Infections and Infectious Diseases Product Name: Vascepa
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Amarin
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2020
Details:
Health Canada has approved HLS Therapeutics' PERSERIS® (risperidone for extended-release injectable suspension), 90 mg and 120 mg subcutaneous injection, a novel long-acting injectable of risperidone, for the treatment of schizophrenia in adults.
Lead Product(s): Risperidone
Therapeutic Area: Psychiatry/Psychology Product Name: Perseris
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2020
Details:
HLS has acquired certain entities that hold the rights to a diversified portfolio of royalty interests on global sales of four different products, this includes Takeda Pharmaceutical's Obizur, a porcine recombinant Factor VIII for acquired hemophilia A.
Lead Product(s): Porcine recombinant Factor VIII
Therapeutic Area: Genetic Disease Product Name: Obizur
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Takeda Pharmaceutical
Deal Size: $49.3 million Upfront Cash: $30.8 million
Deal Type: Acquisition September 30, 2020
Details:
If approved by Health Canada, PERSERIS would become the first once-monthly risperidone long-acting injectable used in the treatment of schizophrenia.
Lead Product(s): Risperidone
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
